GYPA and type 2 diabetes mellitus: We established that among T2DM patents with HF and AF significantly lower levels of CD235a+ PS+ RBC-derived vesicles were detected in those with HbA1c < 6.9% (410 ± 80 particles in μL) than in patients with HbA1c ≥ 7.0% (574 ± 92 particles in μL).